Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 1834906 trials

ENZYCHEM LIFESCIENCES CORPORATION

Official website

KOSDAQ-listed pharma-biotech developing the EC-18 drug pipeline alongside API, health-functional-food, and bio-oil businesses.

As of 2026-10-08, ENZYCHEM LIFESCIENCES CORPORATION has 31 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded in 1999 and listed on KOSDAQ in 2018, Enzychem Lifesciences is a pharma-biotech company focused on global new drug development and pharmaceuticals. It is developing its drug candidate EC-18 as a treatment for chemoradiation-induced oral mucositis (CRIOM), acute radiation syndrome (ARS), and atopic dermatitis (AD), alongside active pharmaceutical ingredients such as erdosteine and gadobutrol, the health-functional food 'Rokpid Immune,' and a bio-oil business (HVO/SAF feedstock) run by its subsidiary Shinheung Co. Its current revenue mix is 33.8% from APIs and 66.2% from bio-oil, and it has registered more than 40 API products with Korea's Ministry of Food and Drug Safety, exporting to China, India, Russia, and other markets.

Products & technology

  • EC-18Drug candidate for CRIOM, ARS, and atopic dermatitis
  • ErdosteineExpectorant
  • GadobutrolMRI contrast agent
  • D-CycloserineAnti-tuberculosis agent
  • SarpogrelateAnticoagulant
  • Zinc CarnosineAnti-ulcer agent
  • ZaltoprofenAnti-inflammatory analgesic
  • Rokpid Immune / Immune VitaminIndividually-approved health functional food based on deer-antler-derived PLAG for immune modulation

Clinical trials

data.go.kr

6 MFDS clinical trial authorisations · 2014–2024 (Phase 2 3 · Phase 1 2 · Phase 1/2 1)

  • Phase 2EC-182024-10-30

    1 trial site

  • Phase 2EC-182020-05-12

    5 trial sites

  • Phase 2EC-182020-04-02

    1 trial site

  • Phase 1/2EC-182016-12-02

    6 trial sites

  • Phase 1EC-182015-07-21

    1 trial site

  • Phase 1EC-182014-06-12

    1 trial site

Global clinical trials

ClinicalTrials.gov · sponsor-matched

R&D and key agreements

Source: DART corporate disclosure

EC-18 · CRIOM/ARS/AD · 비임상·임상 진행중 · Mechanism-based candidate under development for multiple indications

AI 기반 혁신신약 발굴 플랫폼 및 세노테라퓨틱스 · 연구단계(2024년부터) · AI-driven drug discovery platform and senotherapeutics research since 2024

DAC(Degrader-Antibody Conjugates) · 연구 포트폴리오 편입(2025년 4분기) · Antibody-based degrader conjugate technology; expanding into ADC and PROTAC modalities

Key disclosures

KRX KIND via OpenDART
Show 15 more events

Publications

PubMed · affiliation-matched
Show 21 more publications

Patents

KIPRIS · applicant-matched
Show 218 more patents

AI reads

MAA server logs · IP-verified
24
Times AI engines pulled ENZYCHEM LIFESCIENCES CORPORATION's records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

1
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

23
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

4
live 1
Last 7 days
18
live 1
Last 30 days
24
live 1
All time
  • OpenAIChatGPT-Userlive1
  • OpenAIOAI-SearchBot18
  • PerplexityPerplexityBot2
  • AnthropicClaudeBot2
  • GoogleGoogleOther1

Measured since Aug 27, 2026 · 4 AI engines · last read Oct 7, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for ENZYCHEM LIFESCIENCES CORPORATION and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · regulatory approvals. Send us materials and we will add them

Companies in the same categoryBiotech & Drug Discovery

AHNLAB,INC.100

KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.

Inventage Lab Inc.100

Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.

ORGANOIDSCIENCES LTD.100

Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.

Eone Diagnomics Genome Center Co., Ltd.85

EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.

SK Chemicals Co., Ltd.85

A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.

CG Invites Co., Ltd.85

Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.

Y-Biologics, Inc85

KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.

GC Corp.85

A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.

Prestige BioPharma Limited85

Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.

GENEMATRIX INC.85

KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.

SillaJen, Inc.85

SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.

SK Bioscience Co.,Ltd84

A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition